Resectable solid tumor
Conditions
Interventions
None listed
Sponsors
National Cancer Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patient is 18 years of age or older at the time of obtaining consent. 2. The patient has been diagnosed with one of the following resectable malignant solid tumors, at clinical stage I-IV Gastric cancer, pancreatic cancer, liver cancer, breast cancer, ovarian cancer, endometrial cancer, and urothelial cancer (bladder cancer and renal pelvis/ureter cancer) 3. The patient is scheduled to undergo curative resection or curative chemotherapy and or chemoradiotherapy. *1 4. The patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. 5. Written informed consent for participation in this study has been obtained from the patient. *1 Patients who are scheduled for curative resection are eligible even if they undergo preoperative chemoradiotherapy or chemotherapy.
Exclusion criteria
Exclusion criteria: 1. The patient has double cancer.*1 2. The patient is pregnant. 3. The patient has a history of, or concurrent, other malignancies within 3 years prior to enrollment. 4. The patient has serious comorbidities (e.g., uncontrolled diabetes or infections, symptomatic interstitial pneumonia or pulmonary fibrosis, etc.). 5. The patient is deemed by the principal investigator to be otherwise inappropriate for participation in this study. *1: Includes synchronous or multiple cancers, as well as metachronous cancers with a disease-free interval of less than 3 years. However, the following histories are not considered active double/multiple cancers, even if the disease-free interval is less than 3 years, provided they have been completely resected and correspond to the pathological stages listed below: Gastric cancer (adenocarcinoma, common type): Stage 0-I Colon cancer (adenocarcinoma): Stage 0-I Rectal cancer (adenocarcinoma): Stage 0-I Esophageal cancer (squamous cell carcinoma, adenosquamous carcinoma, basaloid carcinoma): Stage 0 Breast cancer (DCIS, LCIS): Stage 0 Breast cancer (invasive ductal carcinoma, invasive lobular carcinoma, Paget disease): Stage 0-IIA Endometrial cancer (endometrioid adenocarcinoma, mucinous adenocarcinoma): Stage I Prostate cancer (adenocarcinoma): Stage I-II Cervical cancer (squamous cell carcinoma): Stage 0 Thyroid cancer (papillary carcinoma, follicular carcinoma): Stage I-III Renal cancer (clear cell carcinoma, chromophobe carcinoma): Stage I Other lesions equivalent to carcinoma in situ of mucosal origin Staging is based on the UICC-TNM Classification, 8th Edition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The association between molecular profiles in blood and tumor tissue such as genomic alterations, RNA expression, and molecular residual disease (MRD), and recurrence status or clinical outcomes. | — |
Secondary
| Measure | Time frame |
|---|---|
| The relationships among molecular profiles in blood and tumor tissue such as genomic alterations, RNA expression, and molecular residual disease (MRD), and their associations with therapeutic efficacy, treatment course, imaging findings, pathological findings, and other clinicopathological factors. | — |
Countries
Japan
Contacts
Public ContactTadayoshi Hashimoto
National Cancer Center Hospital East Department for the Promotion of Drug and Diagnostic Development
Outcome results
None listed